Regeneron announces FDA accepted for review BLA for odronextamab

Regeneron (REGN) Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted for review the resubmission of the Biologics License Application, BLA, for odronextamab in relapsed/refractory follicular lymphoma, FL, after two or more lines of systemic therapy. The target action date for the FDA decision is July 30, 2025.